OrbiMed Advisors LLC's Form 4 filing
Damora Therapeutics, Inc. (DMRA) · filed Aug 17, 2023
- Accession no.
- 0000947871-23-000873
- Filed
- Aug 17, 2023, 4:40 PM ET
- Trade date
- Aug 15, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market sales total $617.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| OrbiMed Advisors LLCCIK 0001055951 | 10% Owner |
| OrbiMed Israel GP II, L.P.CIK 0001682090 | 10% Owner |
| OrbiMed Advisors Israel II LtdCIK 0001682093 | 10% Owner |
| OrbiMed Capital GP VII LLCCIK 0001760648 | 10% Owner |
| OrbiMed Genesis GP LLCCIK 0001808744 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 15, 2023 | Common Stock | SSaleDisposed | −38,327 | $0.75 | −$28,745.25 | 97,204 | Indirect | |
| Aug 15, 2023 | Common Stock | SSaleDisposed | −248,819 | $0.75 | −$186,614.25 | 631,048 | Indirect | |
| Aug 15, 2023 | Common Stock | SSaleDisposed | −535,534 | $0.75 | −$401,650.5 | 1,510,375 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.